Revolution Medicines, Inc. (RVMD) Debt Components
- 2025-06-30: Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Debt Instrument, Basis Spread on Variable Ratepure 6 month · 5.75%.
- 2025-06-30: Line of Credit Facility, Maximum Borrowing CapacityUSD $750.00M; Debt Instrument, Basis Spread on Variable Ratepure (m).
Revolution Medicines, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Line of Credit Facility, Maximum Borrowing Capacity USD | Debt Instrument, Basis Spread on Variable Rate pure |
|---|---|---|
| 2025-06-30 | (m) | 6 month · 5.75% |
| 2025-06-30 | $750.00M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |